NIH-funded research R21 grant

Targeted lysosomal RNA degradation for disease-relevant RNAs

Official title: Targeted lysosomal degradation of RNA

Funded at Tufts University Medford · NIH-11445383 · Data updated 2026-11-12

A new approach uses tiny molecules to tag specific RNAs for destruction inside cells, with the goal of helping diseases linked to RNA problems.

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionTufts University Medford
NIH-funded
Lab location1 site (Boston, UNITED STATES)
Project startAugust 1, 2026
Project endJuly 31, 2028
Funding year2026
Award (this year)$374,866
NIH project number1R21TR006446-01
Project IDNIH-11445383 on NIH RePORTER

Who could benefit from this research

Could help

Ideal participants would be individuals whose disease involves RNA-guided pathology and could plausibly benefit from RNA-targeting therapies in future development.

Less likely to help

Patients with conditions unlikely to be affected by RNA-targeting therapies or those without access to future trials may not benefit.

What this research studies

This project proposes a novel way to remove harmful RNA molecules by guiding them to the cell’s lysosome for breakdown. It builds on recent RNA-binding molecules and combines them with the cell’s degradation machinery to create a therapeutic strategy. By targeting RNA via autophagy (RNAphagy), the work aims to affect RNAs involved in disease while aiming to minimize harming healthy cells. The R21 study will explore safety, feasibility, and initial signals of efficacy in cellular and potentially animal models. If successful, this could open a new class of RNA-focused treatments.

Why it matters

Potential benefit: If successful, patients could benefit from new RNA-targeting therapies that reduce the harmful effects of disease-related RNAs.

How similar studies have gone: Preliminary work shows RNA-targeting approaches can work for specific RNAs, but broad, lysosome-based RNA degradation is a novel direction with early, promising signals.

Where this research is happening

  • Tufts University Medford
    Boston, United States
    Active

Researchers

  • Principal investigator: Kritzer, Joshua a — Tufts University Medford
  • Study coordinator: Kritzer, Joshua a

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.